A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs PBI 4050 (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors ProMetic Life Sciences
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 15 Mar 2017 Status changed from planning to not yet recruiting.
- 16 Nov 2016 According to a ProMetic Life Sciences media release, company has received clearance by Health Canada to commence this study.